Search - tctmd.com

Displaying 741 - 760 of 1466

Sort: Relevancy | Date

Presentation TCT 2018

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

Presenter: Saibal Kar, Horst Sievert, Krzysztof Bartus

September 24, 2018

Presentation TCT 2018

The Watch TAVR Trial: Rationale, Design and Status

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Samir R. Kapadia

September 24, 2018

Presentation TCT 2018

The WaveCrest Device and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Gregg W. Stone

September 24, 2018

Presentation TCT 2018

The Amulet Platform, Experience and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Apostolos Tzikas

September 24, 2018

Presentation TCT 2018

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

Presenter: Vivek Y. Reddy, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

FDA Perspectives on New Devices and Indications for LAA Closure

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Andrew Farb

September 24, 2018

Presentation TCT 2018

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Paul D. Varosy

September 24, 2018

Presentation TCT 2018

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Presenter: James B. Hermiller Jr, David Hildick-Smith, George S. Hanzel

September 24, 2018

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation TCT 2018

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, David E. Thaler

September 24, 2018

Presentation TCT 2018

LAA Closure 3: Prevention and Management of Complications

Presenter: Habib Gamra, E. Murat Tuzcu

September 23, 2018

Presentation TCT 2018

LAA Closure 2: Step-by-step

Presenter: Habib Gamra, E. Murat Tuzcu, Hazem Khamis

September 23, 2018

Presentation TCT 2018

LAA Closure 1: State-of-the-art

Presenter: Habib Gamra, E. Murat Tuzcu

September 23, 2018

Presentation TCT 2018

Take-Home Messages: What Did We Learn From These Cases?

Presenter: Maurice Buchbinder, Vivek Y. Reddy

September 23, 2018

Presentation TCT 2018

Case #12: An LAA Exclusion Procedure Guided by Personalized Computer Modeling

Presenter: Maurice Buchbinder, Vivek Y. Reddy, Habib Gamra, Aaron V. Kaplan, Ulf Landmesser, Petr Neuzil, Jai-Wun Park, Kolja Sievert

September 23, 2018

Presentation TCT 2018

Case #11: Major Complication of an LAA Closure Procedure in a Frail, Elderly Patient

Presenter: Maurice Buchbinder, Vivek Y. Reddy, Habib Gamra, Aaron V. Kaplan, Ulf Landmesser, Petr Neuzil, Jai-Wun Park, Kolja Sievert

September 23, 2018

Presentation TCT 2018

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Presenter: Horst Sievert, Brian K. Whisenant, Fabian Nietlispach

September 23, 2018

Presentation TCT 2018

Case #11: An Unexpected Complication During LAA Closure

Presenter: Samir R. Kapadia, Bernard Prendergast, Eric Eeckhout, Ganesh Manoharan, John C. Messenger, Bernhard Reimers, Paul Sorajja, Eric Vang

September 23, 2018

Advertisement

Epicardial LAA closure: From Surgical Results to Transpericardial Applications

The Watch TAVR Trial: Rationale, Design and Status

The WaveCrest Device and US Pivotal Trial

The Amulet Platform, Experience and US Pivotal Trial

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

FDA Perspectives on New Devices and Indications for LAA Closure

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

LAA Closure 3: Prevention and Management of Complications

LAA Closure 2: Step-by-step

LAA Closure 1: State-of-the-art

Take-Home Messages: What Did We Learn From These Cases?

Case #12: An LAA Exclusion Procedure Guided by Personalized Computer Modeling

Case #11: Major Complication of an LAA Closure Procedure in a Frail, Elderly Patient

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Case #11: An Unexpected Complication During LAA Closure

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content